⌘K

Login Start Free

Home/Filings/4/0000899243-18-011945

4//SEC Filing

BURR ROBERT L 4

Accession 0000899243-18-011945

CIK 0001723128other

View on SEC.gov Company Profile

Filed

May 7, 8:00 PM ET

Accepted

May 8, 7:23 PM ET

Size

31.2 KB

Accession

0000899243-18-011945

Insider Transaction Report

Form 4

Period: 2018-05-04

Amneal Pharmaceuticals, Inc.AMRX

Director

Transactions

Award
Stock Option
2018-05-04+10,000→ 10,000 total
Exercise: $27.97Exp: 2021-05-11→ Class A Common Stock (10,000 underlying)
Award
Class A Common Stock
2018-05-04+6,057→ 6,057 total(indirect: By IRA)
Award
Stock Option
2018-05-07+24,977→ 24,977 total
Exercise: $15.01Exp: 2028-05-07→ Class A Common Stock (24,977 underlying)
Award
Stock Option
2018-05-04+10,575→ 10,575 total
Exercise: $30.33Exp: 2026-05-17→ Class A Common Stock (10,575 underlying)
Award
Stock Option
2018-05-04+12,000→ 12,000 total
Exercise: $17.99Exp: 2023-05-15→ Class A Common Stock (12,000 underlying)
Award
Stock Option
2018-05-04+10,000→ 10,000 total
Exercise: $20.90Exp: 2022-05-23→ Class A Common Stock (10,000 underlying)
Award
Class A Common Stock
2018-05-04+60,475→ 60,475 total
Award
Stock Option
2018-05-04+7,300→ 7,300 total
Exercise: $44.85Exp: 2025-05-12→ Class A Common Stock (7,300 underlying)
Award
Stock Option
2018-05-04+10,000→ 10,000 total
Exercise: $20.30Exp: 2020-05-26→ Class A Common Stock (10,000 underlying)
Award
Stock Option
2018-05-04+30,000→ 30,000 total
Exercise: $6.55Exp: 2019-05-20→ Class A Common Stock (30,000 underlying)
Award
Restricted Stock Units
2018-05-07+6,107→ 6,107 total
→ Class A Common Stock (6,107 underlying)
Award
Stock Option
2018-05-04+11,500→ 11,500 total
Exercise: $25.24Exp: 2024-05-14→ Class A Common Stock (11,500 underlying)
Award
Stock Option
2018-05-04+10,575→ 10,575 total
Exercise: $16.40Exp: 2027-05-16→ Class A Common Stock (10,575 underlying)

Footnotes (7)

[F1]Received in exchange for 60,475 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA").
[F2]Received in exchange for 6,057 shares of Impax common stock pursuant to the BCA.
[F3]The option is vested and currently exercisable.
[F4]Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock.
[F5]The option vests in four equal annual installments beginning on May 07, 2019.
[F6]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
[F7]The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Amneal Pharmaceuticals, Inc.

CIK 0001723128

Entity typeother

Related Parties

1

filerCIK 0001245188

Filing Metadata

Form type: 4
Filed: May 7, 8:00 PM ET
Accepted: May 8, 7:23 PM ET
Size: 31.2 KB

View on SEC.gov